, Volume 35, Issue 1, pp 83–91 | Cite as

Alopecia and Hirsuties

Current Concepts in Pathogenesis and Management
  • Julian H. Barth
Practical Therapeutics


Hirsuties and androgenic alopecia are the patterns of hair growth in women which develop in a similar manner to that normally seen in men. This process is mediated by androgens. It may be due to increased hormone production or increased target organ sensitivity.

The majority of patients with hirsuties may be adequately managed with a careful explanation of their condition and advice about depilatory techniques. Some will benefit from a course of systemic antiandrogen therapy, but hair growth will resume on cessation of therapy.

There have been few objective studies to evaluate the benefits of antiandrogen therapy in female baldness and none with minoxidil.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barth JH, Cherry CA, Dawber RPR, Wojnarowska F. Clinical and laboratory manifestations of cutaneous virilism. British Journal of Dermatology 115 (Suppl. 30): 40–41, 1986Google Scholar
  2. Boisselle A, Tremblay RR. New therapeutic approach to the hirsute patient. Fertility and Sterility 32: 276–279, 1979PubMedGoogle Scholar
  3. Braendle W, Boess H, Breckwoldt M, Leven C, Bettendorf G. Wirkung und neben Wirkung der cyproteroneacetatbehandlung. Archiv für Gynakologie 216: 335, 1974PubMedCrossRefGoogle Scholar
  4. Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. British Journal of Dermatology 112: 124–125, 1985PubMedCrossRefGoogle Scholar
  5. Chrousos GP, Loriaux DL, Mann DL, Cutler Jr GB. Late onset 21-hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease: an allelic variant of congenital virilizing adrenal hyperplasia with a milder enzymatic defect. Annals of Internal Medicine 96: 143–148, 1982PubMedGoogle Scholar
  6. Cullberg G, Hamberger L, Mattsson L-A, Mobacken H, Samsioe G. Low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica 64: 195–202, 1985PubMedCrossRefGoogle Scholar
  7. Dawber RPR, Sonnex T, Ralfs I. Oral anti-androgen treatment of common baldness in women. British Journal of Dermatology 107 (Suppl. 22): 20, 1982Google Scholar
  8. De Villez RL. Topical minoxidil therapy in hereditary androgenetic alopecia. Archives of Dermatology 121: 197–202, 1985PubMedCrossRefGoogle Scholar
  9. De Villez RL, Dunn J. Female androgenic alopecia: the 3 alpha-17 beta-androstanediol glucuronide/sex hormone binding globulin ratio as a possible marker for female pattern baldness. Archives of Dermatology 122: 1011–1015, 1986PubMedCrossRefGoogle Scholar
  10. Dorrington-Ward P, McCartney ACE, Holland S, Scuuly J, Carter G, et al. The effect of spironolactone on hirsutism and female androgen metabolism. Clinical Endocrinology 23: 161–167, 1985PubMedCrossRefGoogle Scholar
  11. Ekoe JK, Burckhardt P, Ruedi B. Treatment of hirsutism, acne and alopecia with cyproterone acetate. Dermatologica 160: 398–404, 1980PubMedCrossRefGoogle Scholar
  12. Evans DJ, Barth JH. Altered body morphology in androgenised women. International Journal of Obesity, in press, 1987Google Scholar
  13. Evans DJ, Burke CW. Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. Journal of the Royal Society of Medicine (London) 79: 451–453, 1986Google Scholar
  14. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology 21: 1440–1447, 1961CrossRefGoogle Scholar
  15. Flier JS, Eastman RC, Minaker KL, Matteson D, Rowe JW. Acanthosis nigricans in obese women with hyperandrogenism. Diabetes 34: 101–107, 1985PubMedCrossRefGoogle Scholar
  16. Gompel A, Wright F, Kuttenn F, Mauvais-Jarvis P. Contribution of plasma androstenedione to 5-androstanediol glucuronide in women with idiopathic hirsuties. Journal of Clinical Endocrinology and Metabolism 62: 441–444, 1986PubMedCrossRefGoogle Scholar
  17. Hamilton J. Male hormone is a prerequisite and an incitant in common baldness. American Journal of Anatomy 71: 451, 1942CrossRefGoogle Scholar
  18. Hamilton JB. Patterned loss of hair in man: types and incidence. Annals of the New York Academy of Sciences 53: 708–728, 1951PubMedCrossRefGoogle Scholar
  19. Holmes P. The fats of life. Cosmopolitan, pp. 6–7, January 1986Google Scholar
  20. Kirschner MA, Jacobs JB. Combined ovarian and adrenal vein catheterisation to determine site(s) of androgen overproduction in hirsute women. Journal of Clinical Endocrinology and Metabolism 33: 199–209, 1971PubMedCrossRefGoogle Scholar
  21. Kligman AM. Pathologic dynamics of human hair loss. Archives of Dermatology 83: 175–198, 1961PubMedCrossRefGoogle Scholar
  22. Kusick JM, Bergfield WF, Steck WD, Gupta MK. Adrenal androgenic female-pattern alopecia: sex hormones and the balding woman. Cleveland Clinic Quarterly 50: 111–122, 1983Google Scholar
  23. Kuttenn F, Couillin P, Girard F, Billaud L, Vicens M, Boucekkine C, et al. Late-onset adrenal hyperplasia in hirsutism. New England Journal of Medicine 313: 224–231, 1985PubMedCrossRefGoogle Scholar
  24. Lobo RA, Goebelsmann U. Adult manifestation of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycystic ovarian disease. American Journal of Obstetrics and Gynecology 138: 720–726, 1980PubMedGoogle Scholar
  25. Lobo RA, Goebelsmann U, Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 57: 393–397, 1983PubMedCrossRefGoogle Scholar
  26. Lobo RA, Shoupe D, Serafino P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertility and Sterility 43: 200–205, 1985PubMedGoogle Scholar
  27. Lucky AW, Rosenfield RL, McGuire J, Rudy S, Heike J. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. Journal of Clinical Endocrinology and Metabolism 62: 840–848, 1986PubMedCrossRefGoogle Scholar
  28. Ludwig E. Classification of the types of androgenic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology 97: 247–254, 1977PubMedCrossRefGoogle Scholar
  29. Lunde O, Grottum P. Body hair growth in women: normal or hirsute. American Journal of Physical Anthropology 64: 307–313, 1984PubMedCrossRefGoogle Scholar
  30. McKnight E. The prevalence of ‘hirsutism’ in young women. Lancet 1: 410–413, 1964PubMedCrossRefGoogle Scholar
  31. Molinatti GM, Messina M, Manieri C, Massucchetti C, Biffignandi P. Current approaches to the treatment of virilising syndromes. In Molinatti et al. (Eds) Androgenization in women, pp. 179–193, Raven Press, New York, 1983Google Scholar
  32. Montagna W, Parakkal PF. The pilary apparatus. In Montagna & Parakkal (Eds) The structure and function of skin, 3rd ed., pp. 172–258, Academic Press, New York, 1974Google Scholar
  33. Mortimer CH, Rushton H, James KC. Effective medical treatment for common baldness in women. Clinical and Experimental Dermatology 9: 342–350, 1984PubMedCrossRefGoogle Scholar
  34. Mortimer PS, Dawber RPR, Gales MA, Moore RA. Mediation of hidradenitis suppurativa by androgens. British Medical Journal 292: 245–248, 1986PubMedCrossRefGoogle Scholar
  35. Mowsowicz I, Riahi M, Wright F, Bouchard P, Kuttenn F, et al. Androgen receptor in human skin cytosol. Journal of Clinical Endocrinology and Metabolism 52: 338–344, 1981CrossRefGoogle Scholar
  36. Nuck BA, Fogelson SL, Lucky AW. Topical minoxidil does work as an anti-androgen in the flank organ of the golden Syrian hamster. Archives of Dermatology 123: 59–61, 1987PubMedCrossRefGoogle Scholar
  37. Olsen EA, Weiner MS, Delong ER, Pinnell SR. Topical minoxidil in early pattern baldness. Journal of the American Academy of Dermatology 13: 185–192, 1985PubMedCrossRefGoogle Scholar
  38. Pedersen J. Hypertrichosis in women. Acta Dermato-VenereoIogica 23: 1–13, 1943Google Scholar
  39. Pogmore JR, Jequier AM. Effect of varying amounts of ethinyl oestradiol in the combined oral contraceptive on plasma sex hormone binding globulin capacity in normal women. British Journal of Obstetrics and Gynaecology 86: 563–567, 1979PubMedCrossRefGoogle Scholar
  40. Reynolds EL. The appearance of adult patterns of body hair in man. Annals of the New York Academy of Sciences 53: 576–584, 1951PubMedCrossRefGoogle Scholar
  41. Rich BH, Rosenfield RL, Lucky AW, Heike JC, Otto P. Adrenarche: changing adrenal response to adrenocorticotropin. Journal of Clinical Endocrinology and Metabolism 52: 1129–1136, 1981PubMedCrossRefGoogle Scholar
  42. Seago SV, Ebling FJG. The hair cycle on the human thigh and upper arm. British Journal of Dermatology 113: 9–16, 1985PubMedCrossRefGoogle Scholar
  43. Shah PN. Human body hair — a quantitative study. American Journal of Obstetrics and Gynecology 73: 1255–1265, 1957PubMedGoogle Scholar
  44. Shuster S. Primary cutaneous virilism or idiopathic hirsuties? British Medical Journal 2: 285–286, 1972PubMedCrossRefGoogle Scholar
  45. Shuster S, Black MM, Bottoms E. Skin collagen and thickness in women with hirsuties. British Medical Journal 4: 772, 1970PubMedCrossRefGoogle Scholar
  46. Stahl NL, Teeslink CR, Greenblatt RB. Ovarian and adrenal and peripheral testosterone levels in the polycystic ovary syndrome. American Journal of Obstetrics and Gynecology 117: 194–200, 1973PubMedGoogle Scholar
  47. Venning VA, Dawber RPR. Patterned androgenic alopecia in normal women. In press, 1987Google Scholar
  48. Vigersky RA, Mehlman I, Glass AR, Smith CE. Treatment of hirsute women with cimetidine. New England Journal of Medicine 303: 1042, 1980PubMedCrossRefGoogle Scholar
  49. Wajchenberg BL, Achando SS, Okada H, Czeresnia CE, Peixoto S, et al. Determination of the source(s) of androgen overproduction in hirsutism associated with polycystic ovary syndrome by simultaneous adrenal and ovarian venous catheterization: comparison with the dexamethasone suppression test. Journal of Clinical Endocrinology and Metabolism 63: 1204–1210, 1986PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1988

Authors and Affiliations

  • Julian H. Barth
    • 1
  1. 1.Department of DermatologyThe Slade HospitalOxfordEngland

Personalised recommendations